Early Signs For Takeda’s TAK-875 Suggest The GPR40 Agonist Could Take On Other Oral Antidiabetics

Takeda’s novel GPR40 agonist TAK-875 has proven in Phase II to have blood sugar lowering on par with widely prescribed sulfonylureas, without causing hypoglycemia, and now moves into Phase III.